<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400190</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2014.111</org_study_id>
    <nct_id>NCT02400190</nct_id>
  </id_info>
  <brief_title>The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)</brief_title>
  <official_title>The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rutgers Cancer Institute of New Jersey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect rates of local/regional recurrence in select patients who do not
      receive radiation treatment after lumpectomy surgery. These women must be postmenopausal;
      have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal
      to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect
      prospective data supporting the idea that this is a population at sufficiently low risk of
      local/regional recurrence that omission of adjuvant radiation might be a reasonable option.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study's primary aim is to determine rates of recurrence with the innovative approach of
      considering tumor biology to select patients who may avoid radiation, with restriction of
      eligibility to women aged 50-69 with hormone-sensitive, Her2-negative tumors with Oncotype-DX
      RS ≤ 18 who plan to receive endocrine therapy. In this way, this study seeks to collect
      prospective data supporting the idea that this is a population at low risk of LRR in whom
      omission of adjuvant radiation is reasonable.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco-regional Recurrence</measure>
    <time_frame>5 years of follow up</time_frame>
    <description>All patients will be followed for their clinical outcome for at least 10 years, specifically: for development of recurrence (and site), the salvage therapy type if local disease recurs, for development of distant metastasis, and survival - both overall and breast-cancer specific.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Endocrine therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive endocrine therapy alone without radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endocrine therapy alone without radiotherapy</intervention_name>
    <description>Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.</description>
    <arm_group_label>Endocrine therapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
             age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
             menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
             status.

          -  Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
             breast conserving surgery

          -  Negative axillary nodes (isolated tumor cells with no cluster measuring &gt;0.2mm
             allowed)

               -  Allowable options for axillary staging include:

               -  Sentinel node biopsy only

               -  Sentinel node biopsy followed by axillary dissection

               -  Axillary dissection only

          -  Margins of excision ≥2mm

          -  ER+, PR+, Her2 - using the current College of American Pathologists guidelines

          -  Oncotype-DX RS ≤ 18

          -  Disease must be unifocal on clinical, radiologic, and pathologic examination

          -  Registration within 90 days of last surgical procedure for breast cancer treatment

          -  Patient must willingly sign study specific informed consent prior to study entry

          -  Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
             years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
             therapy after lumpectomy are eligible.

          -  Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
             within 6 months and contralateral breast within 1 year of study entry.

          -  Patient must have Zubrod performance status 0-2

        Exclusion Criteria:

          -  Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
             negative. Note that MRI is not required for this study, but if performed, evidence of
             disease beyond the site of the primary tumor in the ipsilateral breast or in the
             contralateral breast must be biopsy-proven not to be malignant before registration.

          -  Metastatic disease. Note that no specific staging studies are mandated, but any
             studies performed must not provide clear evidence of metastatic spread.

          -  Previous radiation therapy to the breast region

          -  Prior DCIS or invasive breast cancer

          -  Bilateral breast cancer

          -  Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
             has been no evidence of disease for at least 5 years

          -  Known carrier of a mutation known to predispose towards breast cancer development
             (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
             this protocol; this criterion applies only to patients who have been tested and have
             known carrier status.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reshma Jagsi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reshma L Jagsi, M.D., Ph.D.</last_name>
    <phone>734-936-4300</phone>
    <email>rjagsi@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jody L Sharp, B.S.</last_name>
    <phone>734-615-4909</phone>
    <email>sharpjd@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Horst, M.D.</last_name>
      <email>kateh@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meena Moran, M.D.</last_name>
      <email>meena.moran@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarita Thomas, MD</last_name>
      <email>tathomas@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Wright, MD</last_name>
      <email>jeanwright@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harvard University</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abe Recht, M.D.</last_name>
      <email>arecht@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reshma Jagsi, M.D., Ph.D.</last_name>
      <phone>734-936-4300</phone>
      <email>rjagsi@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jody L Sharp, B.S.</last_name>
      <phone>734-615-4909</phone>
      <email>sharpjd@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Haffty, M.D.</last_name>
      <email>hafftybg@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucille N Lee, M.D.</last_name>
      <phone>516-321-3035</phone>
      <email>LLee3@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud El-Tamer, M.D.</last_name>
      <email>ElTamerM@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Harris, M.D.</last_name>
      <email>harrisel@ecu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Freedman, M.D.</last_name>
      <email>Gary.Freedman@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asal Rahimi, M.D.</last_name>
      <email>Asal.Rahimi@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candice Johnstone, M.D.</last_name>
      <email>cjohnstone@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200/JCO.2009.23.7610. Epub 2010 Jan 11.</citation>
    <PMID>20065188</PMID>
  </reference>
  <results_reference>
    <citation>Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.</citation>
    <PMID>12393820</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation</keyword>
  <keyword>lumpectomy</keyword>
  <keyword>favorable biology</keyword>
  <keyword>omission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

